M. J. van der Valk

CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy

P. Kuppen, C. V. D. van de Velde, A. Vahrmeijer, 2021, Diagnostics.

Chemoradiation and Local Excision Versus Total Mesorectal Excision for T2N0 Rectal Cancer

M. Widmar, J. Garcia-Aguilar, C. van de Velde, 2021, Annals of surgery.

Intra-Tumoral Genomic Heterogeneity in Rectal Cancer: Mutational Status Is Dependent on Preoperative Biopsy Depth and Location

I. Nagtegaal, C. V. D. van de Velde, A. Vahrmeijer, 2020, Cancers.

Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study.

C. V. D. van de Velde, G. Beets, A. Renehan, 2020, The Lancet. Oncology.

Psychological distress and quality of life following positive fecal occult blood testing in colorectal cancer screening

A. Stiggelbout, K. Peeters, H. Vasen, 2020, Psycho-oncology.

Disqualification of Neoadjuvant Rectal Score Based on Data of 6596 Patients From the Netherlands Cancer Registry.

H. Putter, C. V. D. van de Velde, G. Beets, 2019, Clinical colorectal cancer.